Navigation Links
Osteotech's MagniFuse(TM) Distributed to 68 U.S. Hospitals as Product Revenue Surpasses $1 Million
Date:3/8/2010

EATONTOWN, N.J., March 8 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic products for regenerative healing, announced today that its MagniFuse™ Bone Graft has generated its first $1 million in revenue during the four month period beginning with the limited launch of the product in late October 2009.  Osteotech began the first phase of its strategic limited launch of MagniFuse with the release of three procedure specific forms for posterior cervical and posterolateral spine fusion and spinal deformity procedures.  Since that time, the Company has successfully executed its multi-step launch strategy and will highlight a national launch at the upcoming American Academy of Orthopaedic Surgeons Annual Meeting in New Orleans, Louisiana.

"We are pleased with the initial, positive surgeon feedback on MagniFuse and based on the convergence of science, technology and economic benefit, we believe MagniFuse's unique characteristics can redefine the area of bone grafting," said Sam Owusu-Akyaw, Osteotech's President and Chief Executive Officer.  "We are equally pleased with the high level of enthusiasm among our sales team as they become educated on MagniFuse's unique features, benefits and competitive price point.  Similarly, we are also rapidly gaining traction in the broader surgeon community as the clinical benefits of MagniFuse become more widely known.  The preliminary human clinical data from the first MagniFuse surgical case just became available and appears to show robust bone formation in a posterolateral spine fusion at the six-month time point.  We believe this early data, complemented by the non-human clinical data we already have and an exceptional product value proposition, will all converge and support continued adoption of MagniFuse by surgeons as a go-to biologic for advanced bone grafting procedures."

About MagniFuse

MagniFuse, which has received clearance from the United States Food and Drug Administration, is Osteotech's new, patented bone graft technology platform that supports a family of products for use when injury or disease creates a need for bone fusion or new bone growth.  The MagniFuse technology platform has a number of distinguishing characteristics:

  • Delivered in a unique, resorbable self-contained delivery system, MagniFuse provides an optimized scaffold that creates a highly exposed surface area comprised of 100% bone material that is shaped and oriented to provide guided bone healing.  
  • Based upon Osteotech's proprietary processing and manufacturing technologies, MagniFuse's patented formulation is derived from allograft source material that contains a higher concentration of multiple natural human growth factors.
  • MagniFuse's self-contained delivery system also allows for targeted bone formation because it reduces graft site migration once implanted.  
  • MagniFuse is also visible in radiographs, thus providing evidence of its proper placement during and after surgery.  

These characteristics and others solve many of the challenges associated with currently marketed competitive products.  

About Osteotech

Osteotech, Inc., headquartered in Eatontown, New Jersey, is a global leader in providing biologic solutions for regenerative medicine to support surgeons and their patients through the development of innovative therapy-driven products that alleviate pain, promote regenerative and biologic healing and restore function.  For further information regarding Osteotech or this press release, please go to Osteotech's website at www.osteotech.com.

Certain statements made throughout this press release that are not historical facts are forward-looking statements (as defined in the Private Securities Litigation Reform Act of 1995) regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the Company's ability to develop and introduce new products, differences in anticipated and actual product and service introduction dates, the ultimate success of those products in the marketplace, the continued acceptance and growth of current products and services, the impact of competitive products and services, the availability of sufficient quantities of suitable donated tissue and the success of cost control and margin improvement efforts. Certain of these factors are detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. All information in this press release is as of March 8, 2010 and the Company does not intend to update this information.

SOURCE Osteotech, Inc.

Back to top

RELATED LINKS
http://www.osteotech.com

'/>"/>

SOURCE Osteotech, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Osteotechs MagniFuse(TM) Technology Used in First U.S. Surgery
2. Osteotech Highlights Three Procedure-Specific MagniFuse(TM) Bone Grafting Products at the NASS 2009 Annual Meeting
3. OTCBB-VHGI Announces LOI to Sell Certain Assets for $10 Million Cash/Stock to WNDM; With Stock Dividend to be Distributed to Shareholders in 2010
4. Cardinal Health Releases New Tool to Combat MRSA Infections in Hospitals
5. Alabama Hospitals Compare Infection Prevention Performance Statewide With New Benchmarking Tool
6. Hydrox Inc., Cardinal Health Issue Nationwide Recall of Alcohol-Free Mouthwash For Hospitals
7. Nationwide Progress Poll Reveals Increased Efforts by Hospitals to Control MRSA Infection
8. Cepheid GeneXpert(R) System and Xpert(TM) MRSA Selected for up to 11 Victoria, Australia Hospitals in Rollout of Start Clean Strategy
9. Resurgent Health and Medical Announces That Childrens Hospitals and Clinics of Minnesota has Ordered 25 CleanTech Automated Handwashing Systems
10. Photos: Sentara Joins 4 U.S. Hospitals in International TARGIT Breast Cancer Trial
11. CDC Analysis Finds Unique Social and Behavior Intervention Helps Reduce MRSA Rates Up to 62% in Study Hospitals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... Feb. 27, 2017  A landmark study ... , MBBS, PhD, FRACS, of  Sydney Heart and ... Sydney will be published in the February 28, ... American College of Cardiology . According to the study, which ... bypass surgery technique (anOPCABG) reduced postoperative stroke ...
(Date:2/27/2017)...  International Biophysics Corporation, a global medical device manufacturer based ... 34% revenue growth in 2016 when compared to the previous ... growth was fueled by its AffloVest® sales in ... of its global sales of surgical product lines. ... enter our 25 th year in delivering high-quality, innovative ...
(Date:2/27/2017)... Md. , Feb. 27, 2017  RegeneRx ... a clinical-stage drug development company focused on tissue ... licensee for RGN-137, GtreeBNT Co., Ltd., received a ... Phase 3 clinical trial design for RGN-137 to ... wound healing gel that incorporates Thymosin beta 4 ...
Breaking Medicine Technology:
(Date:2/27/2017)... Sedona, Arizona (PRWEB) , ... February 27, 2017 ... ... Premier Center for Shamanic Healing and Spiritual Awakening, is happy to announce ... reboot for mind and body, these individual customized retreats offer the winter-weary soul ...
(Date:2/27/2017)... ... 27, 2017 , ... This webinar , sponsored by ... tool to characterize particle size distributions in the field of geoscience and soil ... scientific findings. It describes methods of optimized and standardized sample collection, preparation and ...
(Date:2/27/2017)... ... 27, 2017 , ... Silicon Valley Hair Institute, a professional ... informational post on robotic hair transplantation. San Francisco residents may be confused over ... Unit Transplantation (FUT) can sound similar. Either treatment can be used to provide ...
(Date:2/26/2017)... ... February 26, 2017 , ... This is an ... world’s first to be ISO/IEC 17025:2005 INAB accredited for Der p 1 (house ... is the globally recognised standard that sets out requirements for the technical competence ...
(Date:2/26/2017)... ... February 26, 2017 , ... ODH, Inc.™ announced today it will ... the Sheraton Pentagon City Hotel in Arlington, VA. ODH’s director of medical strategy, Candace ... analytics to improve Medicaid population health management. , ODH will also have an exhibit ...
Breaking Medicine News(10 mins):